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In the United States, pancreatic cancer ranks as
the ﬁfth most common cause of cancer death
in humans of both sexes (American Cancer
Society 2003). Risk factors for pancreatic can-
cer include heritable, germline mutations in
genes such as p16 (Hruban et al. 1999) and
BRCA2 (Risch et al. 2001); cigarette smoking
[International Agency for Research on Cancer
(IARC) 1986]; and a diet consisting of an
increased intake of meat or cholesterol (Howg
and Burch 1996). Recently, Risch (2003)
proposed that the risk of pancreatic cancer is
also increased by prolonged excessive gastric/
duodenal acidity and frequent or repeated
exposure to N-nitroso compounds or their pre-
cursors. Of particular concern are observations
suggesting that chronic pancreatitis may pre-
dispose individuals to cancer of the pancreas.
Chronic pancreatitis, an irreversible
process with permanent loss of pancreatic
function due to fibroinflammatory changes
originating from various factors (Maisonneuve
and Lowenfels 2002), often precedes the
development of pancreatic malignancies. This
chronic condition occurs in tropical regions or
it may result from metabolic or hereditary dis-
orders. Patients suffering from tropical calcify-
ing pancreatitis (a form of nonalcoholic calciﬁc
pancreatitis in adolescents or young adults
with no proven etiologic factor) have a signiﬁ-
cantly increased risk of developing pancreatic
cancer (Chari et al. 1994), suggesting that
chronic pancreatitis is a premalignant disease.
Two independent epidemiologic studies calcu-
lated a 7- to 50-fold increased risk of pancreatic
cancer in patients with hereditary pancreatitis
(Lowenfels et al. 1997). Chronic pancreatic
inﬂammation may also be induced by alcohol,
congenital defects such as cystic ﬁbrosis, some
infectious diseases, drugs, and radiation ther-
apy. Epidemiologic studies support the concept
that inflammation associated with glandular
destruction is a risk factor for exocrine pancre-
atic cancer. Lowenfels et al. (1993) studied
2,015 subjects with chronic pancreatitis and
concluded that the risk of pancreatic cancer is
signiﬁcantly increased in this population and
appears to be independent of sex, country, and
type of pancreatitis. In addition, several envi-
ronmental agents have been proposed as causal
for chronic pancreatitis and pancreatic carcino-
mas and are associated with the wood and pulp
industry, the dry cleaning business, and gaso-
line production and use (Foster et al. 1993; Lin
and Kessler 1981; Milham and Demers 1984).
Polyhalogenated aromatic hydrocarbons
(PHAHs) comprise a large class of compounds
including polychlorinated dibenzodioxins
(PCDDs), polychlorinated dibenzofurans
(PCDFs), polychlorinated biphenyls (PCBs),
polychlorinated naphthalenes, and polybromi-
nated diphenyl ethers. Certain PCDDs,
PCDFs, and coplanar PCBs have the ability to
bind to the aryl hydrocarbon receptor (AhR)
and exhibit biologic actions similar to those of
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD);
they are commonly referred to as dioxin-like
compounds (DLCs). Exposure of humans to
high levels of TCDD has been implicated in
the development of diabetes. According to
one study (Bertazzi et al. 2001), an increase of
diabetes mellitus was suggestively time related
among females in all exposure groups.
Exposure of female Sprague-Dawley rats of
the Spartan strain to 100 ng/kg TCDD for
2y ears was associated with atrophy, ﬁbrosis,
and periarteritis of the pancreas (Kociba et al.
1978), whereas TCDD administered intraperi-
toneally to hamsters at the dose of 100 µm/kg
induced hepatocytic transdifferentiation of the
acinar pancreatic cells (Rao et al. 1988).
Others, however, have observed little or no
correlation between diabetes and dioxin expo-
sure (Steenland et al. 1999).
The National Toxicology Program (NTP)
has recently conducted multiple 2-year life-
time rat bioassays to evaluate the chronic toxi-
city and carcinogenicity of DLCs, structurally
related PCBs, and mixtures of these com-
pounds. Given the known mode of action of
DLCs acting through the AhR, one of the
hypotheses tested in these studies was that
both individual compounds and mixtures
would elicit a similar spectrum of neoplastic
and nonneoplastic responses after chronic
exposure. Our work describes the incidences
and morphologic aspects of pancreatitis and
exocrine pancreatic cancer related to these
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We evaluated the effect of chronic exposure to dioxin and dioxin-like compounds on the pancreas
in female Harlan Sprague-Dawley rats. This investigation represents part of an ongoing National
Toxicology Program initiative to determine the relative potency of chronic toxicity and carcino-
genicity of polychlorinated dioxins, furans, and biphenyls. Animals were treated by gavage for up
to 2 years with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 3,3´,4,4´,5-pentachlorobiphenyl
(PCB-126), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), or a toxic-equivalency-factor (TEF)
mixture of these agents; control animals received corn oil–acetone vehicle alone. A complete
necropsy was performed on all animals, and a full complement of tissues was collected and exam-
ined microscopically. Administration of each of the four compounds was associated with increased
incidences of several nonneoplastic changes in the exocrine pancreas, including cytoplasmic vacuo-
lation, chronic active inﬂammation, atrophy, and arteritis. Low incidences, but higher than those
in the historical database, of pancreatic acinar adenoma and carcinoma were seen in the TCDD,
PeCDF, and TEF-mixture groups. These results indicate that the pancreatic acini are target tissues
for dioxin and certain dioxin-like compounds. Key words: carcinogenesis, dioxin, furans, inﬂam-
mation, pancreas, polychlorinated biphenyls. Environ Health Perspect 112:903–909 (2004).
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Michael E. Wyde,DLCs, as observed in the 2-year toxicity and
carcinogenicity studies.
Materials and Methods
Study design. These studies were conducted
by the NTP (2004) as part of an ongoing
series of chronic 2-year rat bioassays examin-
ing the relative potencies for carcinogenicity
of individual dioxins and mixtures of DLCs.
In these studies, TCDD, 3,3´,4,4´,5-penta-
chlorobiphenyl (PCB-126), 2,3,4,7,8-penta-
chlorodibenzofuran (PeCDF), and a mixture
of TCDD, PCB-126, and PeCDF were tested
at levels based on their toxic equivalency fac-
tors (TEFs); the studies were conducted with
female Harlan Sprague-Dawley rats because
these had been used in prior investigations of
DLCs and because the female rat is more sen-
sitive to the effects of TCDD than the male
(Kociba et al. 1978). The same study design
was used for the TCDD, PCB-126, and
PeCDF studies and included interim evalua-
tion groups, 2-year study groups, and a single
stop-study group that received the highest
dose of chemical. The stop-study group was
added to investigate the potential reversibility
of various pathologic effects induced by these
compounds upon withdrawal of daily admin-
istration and to evaluate whether lesions seen
at the end of the 2 years of study required per-
sistent lifetime exposure (Walker et al. 2000).
The investigation of the tertiary mixture
did not include a stop-study group. Interim
evaluations of 10 animals/group were con-
ducted at weeks 14, 31, and 53 of the study.
The stop-study groups contained 50 animals,
whereas each 2-year study group contained 53.
Animals were dosed once daily for 5 days/week
by oral gavage using the test compound mixed
in a corn oil:acetone vehicle (99:1 vol:vol). The
control animals received the vehicle only. All
animals were dosed for the duration of the
study except for the stop-study animals, which
were dosed for 31 weeks and then given the
vehicle only until study termination at 2 years.
TCDD is the most potent DLC and the
reference compound to which all DLCs are
compared in the TEF methodology. Doses for
the TCDD study were 0, 3, 10, 22, 46, and
100 ng/kg/day; the stop-study dose was
100-stop ng/kg/day. These doses were based on
the TEF values selected by the World Health
Organization (WHO) (Van den Berg et al.
1998). PCB-126 is a non-ortho-substituted
PCB with high bioaccumulation in the food
chain and a TEF value of 0.1. Selected doses of
PCB-126 were 0, 30, 100, 175, 300, 550,
1,000, and 1,000-stop ng/kg/day. PeCDF is a
dioxin-like PHAH with high bioaccumulation
in the food chain and a TEF value of 0.5.
Selected PeCDF doses were 0, 6, 20, 44, 92,
200, and 200-stop ng/kg/day.
The TEF mixture of TCDD, PCB-126,
and PeCDF was designed to test for dose
additivity of induced effects seen for the DLCs
with the highest potency in each of the three
classes of PHAHs covered by the TEF
methodology. Based on average human tissue
levels of these compounds, they represent
approximately 43% of the human tissue bur-
den of the TCDD toxic equivalent (TEQ).
The TEF mixture was composed of equal
ratios (1:1:1) of TEQs for TCDD, PCB-126,
and PeCDF. The TEQ, calculated by multi-
plying the TEF value of each specific com-
pound by the concentration of that compound
in the mixture, results in the TCDD equiva-
lent of that compound. For the TEF mixture,
selected doses were 0, 10, 22, 46, and 100 ng
TEQ/kg/day using the WHO TEF values of
1.0 for TCDD, 0.1 for PCB-126, and 0.5 for
PeCDF. Specific doses used in the TEF-
mixture study were 10 ng TEQ/kg (3.3 ng/kg
TCDD, 6.6 ng/kg PeCDF, 33.3 ng/kg
PCB-126), 22 ng TEQ/kg (7.3 ng/kg TCDD,
14.5 ng/kg PeCDF, 73.3 ng/kg PCB-126),
46 ng TEQ/kg (15.2 ng/kg TCDD,
30.4 ng/kg PeCDF, 153 ng/kg PCB-126),
and 100 ng TEQ/kg (33 ng/kg TCDD,
66 ng/kg PeCDF, 333 ng/kg PCB-126).
Chemicals. TCDD (lot no. CR82-2-2) was
supplied by IIT Research Institute (Chicago,
IL), and PCB-126 (lot no. 130494) by
AccuStandard, Inc. (New Haven, CT).
PeCDF (lot 080196) was purchased from
Cambridge Isotope Laboratories (Cambridge,
MA). For the TEF mixture, we used the same
chemicals  as in the single-compound studies.
The dose formulations were prepared by mixed
volumes of the TCDD, PeCDF, and PCB-126
formulations. Each chemical was received in
one lot that was used for the entire study.
Purity was determined several times during the
study by gas chromatography/mass spec-
troscopy; by nuclear magnetic resonance spec-
troscopy; and by gas chromatography using
ﬂame ionization detection (PCB-126), electron
capture detection (TCDD), proton and 13C
nuclear magnetic spectroscopy (PeCDF), and
gas chromatography/mass spectrometry (TEF
mixture). Purities of TCDD, PCB-126, and
PeCDF, were determined to be approximately
98%, 99.51%, 97%, respectively, with no
change in purity observed over the duration of
the studies. The corn oil was analyzed by
potentiometric titration, and the acetone by
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Table 1. Incidence and average severity of selected pancreatic lesions in rats treated with TCDD.
TCDD dose (ng/kg/day)
Vehicle 100-
control 3 10 22 46 100 stop
14-Week interim evaluation
No. of animals examined 10 10 10 10 10 10
Inﬂammation, chronic active 0 0 0 0 0 2
(no. with lesion) (1.5)
Acinus, atrophy 0 0 0 0 0 2
(no. with lesion) (1.5)
31-Week interim evaluation
No. of animals examined 10 10 10 10 10 10
Acinus, vacuolation cytoplasmic 0 0 0 0 0 5*
(no. with lesion) (1.0)
53-Week interim evaluation
No. of animals examined 8 8 8 8 8 8
Acinus, vacuolation cytoplasmic 0 0 0 0 0 7**
(no. with lesion) (1.0)
Inﬂammation, chronic, active 0 0 0 0 0 2
(no. with lesion) (2.0)
Acinus, atrophy 0 0 0 0 0 2
(no. with lesion) (2.0)
2-Year evaluation
Probability of survival (%) at end of study 47 39 49 36 42 40 42
(Kaplan-Meier determinations)
No. of organs examined 51 54 52 53 53 51 49
Acinus, vacuolation cytoplasmic 1 0 0 1 15** 42** 0***
(no. with lesion) (2.0) (1.0) (1.1) (1.8)
Inﬂammation, chronic active 0 0 2 2 3 6* 4
(no. with lesion) (1.5) (1.0) (1.3) (2.0) (1.5)
Acinus, atrophy 1 2 4 4 4 9* 4
(no. with lesion) (1.0) (1.5) (1.5) (1.5) (1.5) (2.2) (1.8)
Artery, inﬂammation, chronic active 0 1 1 2 2 7* 2
(no. with lesion) (3.0) (2.0) (2.5) (3.0) (2.3) (2.5)
Acinus, adenomaa (no. with lesion) 0 0 0 0 0 1 0
Acinus, carcinomab  (no. with lesion) 0 0 0 0 0 2 1
Lesion severity is shown in parentheses. Grades of lesion severity: 1, minimal; 2, mild; 3, moderate; 4, marked.
aHistorical incidence (pooled control incidence from the four studies) for 2-year gavage studies with Sprague-Dawley
vehicle control group; 1 of 207; range, 0–2%. bHistorical incidence: 0 of 207. *Signiﬁcantly different (p ≤ 0.05) from vehicle
control group by Fisher exact test (interim evaluations) or Poly-3 test (2-year study). **Significantly different (p ≤ 0.01)
from vehicle control group by Fisher exact test (interim evaluations) or Poly-3 test (2-year study). ***Signiﬁcantly different
(p ≤ 0.01) from the 100-ng/kg study group by the Poly-3 test.infrared spectroscopy. Dose formulations were
prepared for gavage administration by mixing
the test chemical in a corn oil vehicle contain-
ing 1% USP-grade acetone. Homogeneity and
stability studies of dose formulations indicated
that all study chemicals could maintain an
acceptable homogeneity for dosing and stabil-
ity for 35 days when stored at room tempera-
ture. Dose formulations analyzed were within
10% of the target concentrations.
Animals. The animal studies were con-
ducted at Battelle Columbus Laboratories
(Columbus, OH). Female Sprague-Dawley
rats, approximately 6 weeks of age, were
obtained from Harlan (Indianapolis, IN). The
animals were held under quarantine for
approximately 2 weeks for health screening
and were approximately 8 weeks of age at the
start of the study. After quarantine, the ani-
mals were randomly assigned to control or
treatment groups and permanently identiﬁed
by tail tattoo. They were housed ﬁve per cage
in solid-bottom polycarbonate cages (Lab
Products, Inc., Maywood, NJ) suspended on
stainless steel racks. Filtered room air under-
went at least 10 changes/hour. Animal rooms
were maintained at 69–75°F with 35–65%
relative humidity and 12 hr of light and 12 hr
of dark. Irradiated NTP-2000 pelleted feed
(Zeigler Bros., Inc., Gardners, PA) and water
were available ad libitum. All animals were
observed twice daily for morbidity checks and
once each month for formal clinical signs of
toxicity; moribund animals were euthanized
and necropsied. The health status of the ani-
mals was monitored by serologic analysis of
serum samples collected from both the study
animals and male sentinel rats placed in the
study rooms. Serum samples remained nega-
tive for any significant rodent pathogen.
Animal husbandry and handling were con-
ducted in accordance with National Institutes
of Health Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory
Animal Resources 1996).
Pathology. At necropsy, all tissues were
examined grossly, any observed lesions were
recorded, and a full complement of tissues was
removed and fixed in 10% neutral buffered
formalin for microscopic evaluation. After ﬁx-
ation, the tissues were trimmed, processed,
embedded in parafﬁn, sectioned at a thickness
of 5 µm, stained with hematoxylin and eosin
(H&E), and examined microscopically. The
severity of lesions was graded on a four-point
scale: 1, minimal; 2, mild; 3, moderate; and 4,
marked. The pathology ﬁndings from all stud-
ies were subjected to a full NTP peer review.
For assuring the consistency of the histopatho-
logic diagnoses among the TEF dioxin pro-
jects, the same study pathologist, quality
assurance pathologist, pathology working
group chairperson, NTP pathologist, and
members of the pathology working group
served in all studies to peer-review the study
pathology ﬁndings.
Statistical analysis. Incidences of lesions in
the study animals were evaluated statistically
by the Poly-3 test of Portier and Bailer (1989)
and Bailer and Portier (1988), which makes
adjustments for survival differences among
groups. Incidences of lesions in animals from
each of the interim evaluations and from the
2-year study were analyzed separately. For ani-
mals in the 2-year studies, the incidences of
total lesions, including ﬁndings from animals
that survived until study termination and
from early-death animals, were included in the
analysis.
Results
Survival data for the 2-year exposures to
TCDD, PCB-126, PeCDF, and the TEF-
mixture studies are given in Tables 1–4.
We observed no signiﬁcant reductions in
survival of test animals relative to control 
animals in any of the four studies. Although
none of the individual dose groups showed a
significant reduction in survival relative to
controls, in the PCB-126 and mixture studies
there was a significant (p < 0.05) decreasing
overall trend in survival, due primarily to a
marginally increased mortality in the highest
dose group relative to the other groups.
Administration of the four compounds
was associated with increased incidences of
Article | Effects of dioxin on rat exocrine pancreas
Environmental Health Perspectives • VOLUME 112 | NUMBER 8 | June 2004 905
Table 2. Incidence and average severity of selected pancreatic lesions in rats treated with PCB-126.
PCB-126 dose (ng/kg/day)
Vehicle 1,000-
control 10 30 100 175 300 550 1,000 stop
31-Week interim evaluation
No. of animals examined 10 10 9 10 10 10 10 10
Inﬂammation, chronic active 0 0 0 0 0 0 0 1
(no. with lesion) (1.0)
Acinus, atrophy 0 0 0 0 0 0 0 1
(no. with lesion) (1.0)
53-Week interim evaluation
No. of animals examined  8 8 7 8 8 8 8 8
Acinus, vacuolation cytoplasmic 0 0 0 0 0 0 1 6*
(no. with lesion) (1.0) (1.0)
Inﬂammation, chronic active 0 0 0 0 0 1 0 1
(no. with lesion) (1.0) (1.0)
Acinus, atrophy 0 0 0 0 0 1 0 1
(no. with lesion) (1.0) (1.0)
2-Year evaluation
Probability of survival (%) at end of study 31 48 49 42 31 43 13 57
(Kaplan-Meier determinations)
No. of animals examined  51 55 53 53 53 52 51 48
Acinus, vacuolation cytoplasmic 0 0 1 4 9** 20** 23** 1***
(no. with lesion) (1.0) (1.5) (1.0) (1.1) (1.4) (1.0)
Inﬂammation, chronic active 5 1 3 4 4 6 13* 4***
(no. with lesion) (1.6) (1.0) (2.0) (1.3) (1.8) (2.3) (2.2) (1.5)
Acinus, atrophy 5 3 2 7 2 11 18** 7***
(no. with lesion) (2.0) (1.3) (2.5) (1.6) (2.5) (2.2) (2.1) (1.4)
Artery, inﬂammation, chronic active 0 4 2 4 8** 15** 11** 1***
(no. with lesion) (2.0) (3.0) (2.5) (2.5) (2.5) (2.9) (2.0)
Acinus, adenoma (no. with lesion) 1 0 0 0 2 0 0 0
Acinus, carcinoma (no. with lesion) 0 0 0 1 0 0 1 0
Lesion severity is shown in parentheses. Grades of lesion severity: 1, minimal; 2, mild; 3, moderate; 4, marked. 
*Signiﬁcantly different (p ≤ 0.05) from vehicle control group by Poly-3 test (2-year evaluation) or Fisher exact test (53-week interim evaluation). **Signiﬁcantly different (p ≤ 0.01) from
vehicle control group by Poly-3 test. ***Signiﬁcantly different (p ≤ 0.01) from 1,000 ng/kg study group by Poly-3 test.nonneoplastic changes of the exocrine pan-
creas, including cytoplasmic vacuolation,
chronic active inflammation, atrophy, and
arteritis, variably observed in the 14-, 31-, and
53-week interim sacrifices and seen in the
2-year studies (Tables 1–4, Figures 1–8). In
addition, low incidences of acinar adenoma
and carcinoma were also seen in the TCDD,
PeCDF, and TEF-mixture studies. The gen-
eral histologic characteristics were comparable
for all chemicals.
Cytoplasmic vacuolation consisted of
small, clear, discrete vacuoles within pancreatic
acinar cells (Figures 2 and 3). Occasionally a
single large vacuole was noted. The severity of
the change was determined by the degree of
vacuolization per cell and the amount of tissue
involved.
Atrophy was a focal to multifocal to diffuse
change consisting of a reduction in the amount
of acinar tissue with an associated increase in
stromal ﬁbrous connective tissue and dilatation
of the ducts (Figures 4, 5, and 7). Chronic
active inﬂammation was generally seen in asso-
ciation with atrophy and consisted of an inﬁl-
trate of mononuclear cells with occasional
neutrophils within the stroma. The islets of
Langerhans were morphologically normal
(Figures 2–4), dispersed throughout the
affected acinar tissue and without reduction in
their number.
Arterial chronic active inﬂammation was a
focal to multifocal change characterized by a
thick mantle of macrophages, lymphocytes,
and plasma cells around the arteries, with inﬁl-
tration into the muscular layers of the artery
(Figure 1) (Jokinen et al. 2003). Fibrinoid
necrosis of the vessel occurred often, and the
tunica intima was frequently thickened.
Endothelial cells were swollen or decreased in
number. This inflammatory reaction often
extended into the surrounding parenchyma.
Adenoma of the acinar cells was character-
ized microscopically by a discrete mass consist-
ing of tubular and acinar structures composed
of small acinar cells with brightly eosinophilic
cytoplasm lacking zymogen granules. In con-
trast, a single case of carcinoma exhibited a
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Table 4. Incidence and average severity of selected pancreatic lesions in rats treated with TEF mixture.
Vehicle TEF dose (ng TEQ/kg/day)
control 10 22 46 100
14-Week interim evaluation
No. of animals examined 10 10 10 10 10
Inﬂammation, chronic active 0 0 0 2 0
(no. with lesion) (1.0)
Acinus, atrophy 0 0 0 0 1
(no. with lesion) (1.0)
31-Week interim evaluation
No. of animals examined 10 10 10 10 10
Acinus, vacuolation cytoplasmic 0 0 0 0 5*
(no. with lesion) (1.0)
Acinus, atrophy 1 1 2 0 0
(no. with lesion) (1.0) (1.0) (1.0)
53-Week interim evaluation
No. of animals examined 8 8 8 8 8
Acinus, vacuolation cytoplasmic 0 0 0 2 7**
(no. with lesion) (1.0) (1.6)
Acinus, atrophy 0 0 0 1 1
(no. with lesion) (2.0) (2.0)
Inﬂammation, chronic active 0 0 0 1 1
(no. with lesion) (3.0) (1.0)
2-Year evaluation
Probability of survival (%) at end of study 30 43 46 44 16
(Kaplan-Meier determinations)
No. of animals examined 52 53 53 53 51
Artery, inﬂammation, chronic active 0 6* 3 8** 14**
(no. with lesion) (2.2) (1.7) (2.6) (2.9)
Acinus, vacuolation cytoplasmic 1 0 3 15** 30**
(no. with lesion) (1.0) (1.3) (1.0) (1.1)
Acinus, atrophy 3 2 7 7 20**
(no. with lesion) (1.3) (1.0) (1.7) (1.7) (2.0)
Inﬂammation, chronic active 3 1 6 7 16**
(no. with lesion) (1.7) (3.0) (1.3) (1.7) (1.8)
Duct, dilatation 0 0 0 0 5*
(no. with lesion) (3.0)
Acinus, adenoma (no. with lesion) 0 0 2 0 0
Acinus, carcinoma (no. with lesion) 0 1 0 2 0
Lesion severity is shown in parentheses. Grades of lesion severity: 1, minimal; 2, mild; 3, moderate; 4, marked. 
*Signiﬁcantly different (p ≤ 0.05) from vehicle control group by Fisher exact test (interim evaluations) or Poly-3 test (2-year
study). **Significantly different (p ≤ 0.01) from vehicle control group by Fisher exact test (interim evaluations) or Poly-3
test (2-year study).
Figure 1. Photomicrograph showing chronic active
inﬂammation of the pancreatic artery from a female
rat administered 1,000 ng/kg/day PCB-126 by gavage
for 2 years. This inflammation is characterized by
transmural infiltration of mixed inflammatory cells
(solid arrows) and ﬁbrinoid necrosis (open arrows).
H&E; bar = 500 µm.
Figure 2. Low magnification photomicrigraph of
pancreatic tissue from a female rat administered
1,000 ng/kg/day PCB-126 by gavage for 2 years.
Cytoplasmic vacuolation (arrows) consists of small,
clear, discrete vacuoles within pancreatic acinar
cells. Apparently normal islets of Langerhans are
indicated by asterisks. H&E; bar = 300 µm.
Table 3. Incidence and average severity of selected pancreatic lesions in rats treated with PeCDF.
PeCDF dose (ng/kg/day)
Vehicle 200-
2-Year evaluation control 6 20 44 92 200 stop
Probability of survival (%) at end of study 47 42 47 48 38 43 30
(Kaplan-Meier determinations)
No. of animals examined 53 53 53 52 52 52 49
Acinus, vacuolation cytoplasmic 0 0 0 0 2 23** 2***
(no. with lesion) (1.0) (1.1) (1.0)
Artery, inﬂammation, chronic active 1 2 1 2 4 11** 1***
(no. with lesion) (1.0) (2.0) (1.0) (2.5) (2.3) (3.3) (2.0)
Acinus, adenoma (no. with lesion) 0 0 0 0 1 0 1
Acinus, carcinoma (no. with lesion) 0 0 0 0 1 0 1
Lesion severity is shown in parentheses. Grades of lesion severity: 1, minimal; 2, mild; 3, moderate; 4, marked.
**Significantly different (p ≤ 0.01) from vehicle control group by Poly-3 test. ***Significantly different (p ≤ 0.01) from
200 ng/kg study group by Poly-3 test.large, multinodular lesion with moderate
amounts of dense ﬁbrous stroma. Carcinomas
appeared composed of densely packed clusters
of poorly formed acinar structures consisting
of small acinar cells with prominent vesicular
nuclei and small amounts of eosinophilic cyto-
plasm with indistinct borders. Scattered solid
areas composed of densely packed, highly
pleomorphic, round to ovoid acinar cells with
large vesicular nuclei and scant cytoplasm also
occurred.
In the TCDD study, treatment-related
nonneoplastic changes were seen at the
31-week interim sacrifice and became pro-
gressively more prominent at the other sacri-
ﬁce periods (Table 1). The incidences of the
nonneoplastic lesions in the stop-exposure
group were less than those in the 100-ng/kg
study group. One acinar adenoma and two
acinar carcinomas were seen in the
100-ng/kg study group. The incidences of
acinar cell carcinoma and adenoma or carci-
noma (combined) exceeded those within 
the historical control range (overall 
incidence of acinar cell adenoma, 1 of 207
or 0.5%, range 0–2%; overall incidence of
acinar cell carcinoma, 0%). A single acinar cell
carcinoma was seen in the stop-exposure group.
In the PCB-126 study, treatment-related
nonneoplastic changes observed at the
31-week sacriﬁce period became progressively
more prominent at the other sacriﬁce periods
(Table 2). We found fewer nonneoplastic
lesions in the stop-exposure group than in
the 1,000 ng/kg study group. In the 2-year
study group, exocrine adenomas and carcino-
mas were observed sporadically in treated
groups but were not related to exposure with
PCB-126. Only one adenoma was observed
in the control group.
At the 2-year sacriﬁce of the PeCDF por-
tion of this investigation, we observed one aci-
nar adenoma and one acinar carcinoma in
both the 92-ng/kg group and the 200-ng/kg
stop-exposure group (Table 3). An increased
incidence of acinar cytoplasmic vacuolation
and increased incidence and severity of arteritis
also occurred in the 92-ng/kg and 200-ng/kg
study groups; the incidence in the 200-ng/kg
stop-exposure study group was significantly
decreased compared with the 200-ng/kg study
group.
In the TEF-mixture group, treatment-
related nonneoplastic changes were seen at the
14-week sacriﬁce period and became progres-
sively worse at the other sacrifice periods
(Table 4). At 2 years, sporadic incidences of
acinar adenoma and acinar carcinoma were
observed in all dosed groups except those
administered 100 ng/kg. The incidence of aci-
nar adenoma in the 22-ng/kg group and the
incidences of acinar carcinoma in the 10-ng/kg
and 46-ng/kg groups exceeded the historical
control ranges (overall incidence of acinar cell
adenoma, 1 of 207 or 0.5%, range 0–2%;
overall incidence of acinar cell carcinoma, 0%).
Discussion
In these studies, we evaluated the effects of
chronic exposure to dioxin and multiple
DLCs on the pancreas in the female Harlan
Sprague-Dawley rat. Our data indicate that
the pancreatic exocrine acini are a target tissue
of the DLCs, inducing mainly degenerative,
inﬂammatory, and atrophic lesions and possi-
bly also sporadic acinar adenomas and carci-
nomas. Despite the low incidences, we found
one pancreatic tumor effect that was statisti-
cally significant (p < 0.001): the increasing
trend in pancreatic acinar cell adenoma/carci-
noma in the TCDD study. Although the mar-
ginal increases in the other studies would not
be particularly noteworthy when considered
individually, it is the consistency of the effects
in all four studies that is important. Only a
single control animal (of 207) had a pancreatic
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Figure 4. Low magniﬁcation photomicrograph of pan-
creas affected by diffuse chronic active inﬂammation
(open arrows) and acinar atrophy (solid arrows) from
a female rat administered 1,000 ng/kg/day PCB-126 by
gavage for 2 years. Chronic active inﬂammation con-
sists of mixed inflammatory cells throughout the
parenchyma; atrophy is characterized by reduction in
the amount of acinar tissue with an associated
increase in stromal fibrous connective tissue and
dilatation of ducts. Apparently unaffected islets of
Langerhans are present throughout affected acinar
tissue (asterisks). H&E; bar = 1,000 µm.
Figure 5. Higher magniﬁcation photomicrograph of
pancreas affected by diffuse chronic active
inflammation (open arrows) and acinar atrophy
(solid arrows) from a female rat administered
1,000 ng/kg/day PCB-126 by gavage for 2 years.
Dilated ducts (D), occasionally containing
sloughed cells, are present throughout the gland.
H&E; bar = 300 µm.
Figure 6. Photomicrograph showing unaffected
acinar tissue (arrows) from a control rat from the
PCB-126 2-year study. A normal islet of Langerhans
is indicated by the asterisk. H&E; bar = 300 µm.
Figure 7. Higher magniﬁcation photomicrograph of
pancreas affected by diffuse chronic active inﬂam-
mation (open arrows) and acinar atrophy (solid
arrows) from a female rat administered 1,000
ng/kg/day PCB-126 by gavage for 2 years. Note the
relatively small area of acinar-cell cytoplasm com-
pared with those in Figure 8 and the interstitial
mixed inflammatory cells. Dilated ducts (D), occa-
sionally containing sloughed cells, are present
throughout the gland. H&E; bar =100 µm.
Figure 8. Photomicrograph showing unaffected
acinar tissue (arrows) from a control rat from the
PCB-126 2-year study. A normal islet of Langerhans
is indicated by the asterisk. H&E; bar = 100 µm.
Figure 3. High magniﬁcation photomicrigraph of pan-
creatic tissue from a female rat administered
1,000 ng/kg/day PCB-126 by gavage for 2 years.
Cytoplasmic vacuolation (arrows) consists of small,
clear, discrete vacuoles within pancreatic acinar
cells. Apparently normal islets of Langerhans are indi-
cated by asterisks. H&E; bar = 100 µm.acincar cell tumor (an adenoma), conﬁrming
that this tumor is relatively uncommon. Yet in
the TCDD, PCB-126, PeCDF, and TEF-
mixture groups, we found four, four, four, and
ﬁve pancreatic acinar cell tumors, respectively,
including two or more carcinomas in each
study. It is this consistency of effect for these
DLCs for a relatively uncommon tumor that
is impressive. The potential copromotional
effect of corn oil on the pancreatic tumors has
been considered (Eustis and Boorman 1985);
however, this association was primarily
reported as a male rat phenomenon, and we
found only 1 adenoma in 362 female rats
treated with corn oil for 2 years and used as
controls in our TEF studies. Majeed (1997)
reported that the historical incidence of
exocrine pancreatic tumors in aged CD female
rats was 0.1% for adenomas and 0.02% for
carcinomas. Two collections of historical data
dealing with the Sprague-Dawley rats
reported zero incidence of pancreatic acinar
tumors (Kaspareit and Rittinghausen 1999;
McMartin et al. 1992). We observed low inci-
dences, but higher than historical levels, of
pancreatic acinar adenoma and carcinoma in
the TCDD, PeCDF, and TEF-mixture stud-
ies (Tables 1, 3, and 4). Both the adenomas
and carcinomas observed in these studies were
exclusively of exocrine acinar cell origin.
Therefore, regarding the pancreatic tumors,
we conclude that there was a marginal increase
in this uncommon tumor in all four studies.
The acinar cell adenomas we observed in
the rats were characterized by being a discrete
mass consisting of tubular and acinar struc-
tures composed of small acinar cells with
brightly eosinophilic cytoplasm and lacking
zymogen granules. In contrast, the acinar cell
carcinoma was a large, multinodular lesion,
with moderate amounts of dense fibrous
stroma. Carcinomas were composed of
densely packed clusters of poorly formed aci-
nar structures consisting of small acinar cells
with prominent vesicular nuclei and small
amounts of eosinophilic cytoplasm with indis-
tinct borders. We also observed scattered solid
areas composed of densely packed, highly
pleomorphic, round-to-ovoid acinar cells with
large vesicular nuclei and scant cytoplasm.
Acinar cell carcinomas do occur rarely in
humans, approximately 1% of all pancreatic
tumors (Solcia et al. 1997); however, the exis-
tence of a benign counterpart, acinar cell ade-
noma, has not been clearly established (Lack
2003a, 2003b). Excluding the rare cases in
children, the average age of adults with acinar
cell carcinoma in two series was 62 years
(Klimstra et al. 1992) and 55 years (Hoorens
et al. 1993). These tumors typically appear to
be well circumscribed and often exhibit coarse
lobulation on cut section, simulating the lobu-
lar character of the normal human pancreas.
Microscopically, the tumor lobules are highly
cellular with scanty stroma, and the tumor cells
may be arranged in acinar, solid, trabecular, or
glandular patterns. These are aggressive neo-
plasms, as indicated by the presence of metas-
tases in about 50% of the patients at the time
of diagnosis, and patients have a 5-year sur-
vival rate of < 10% (Lack 2003b).
In contrast to tumor origin in the
Sprague-Dawley rat, the 80% of all pancreatic
tumors in humans are ductal in origin (ductal
adenocarcinomas). When variants of ductal
adenocarcinoma are included (mucinous non-
cystic carcinoma, adenosquamous carcinoma,
and undifferentiated carcinoma), about 90%
of pancreatic tumors are ductal (Solcia et al.
1997). Most ductal adenocarcinomas are well
to moderately differentiated and, in contrast
to acinar tumors, secrete mucin and elicit a
desmoplastic stromal reaction. Invasion of
peripancreatic retroperitoneal fatty tissue
occurs early in the course of the disease, and
despite surgery, most patients die of tumor
recurrence within 1–2 years (Solcia et al.
1997). Unfortunately, this is not only the
most common of the human pancreatic
tumors but also the most malignant, with an
overall 5-year survival rate in most series of
≤ 2% (Rosai 1996).
Several compounds have been shown to
induce pancreatic tumors in rats, including
nitrofen [National Cancer Institute (NCI)
1978], 3,2´-dimethyl-4-aminobiphenyl (Shirai
et al. 1989), and azaserine (Woutersen et al.
1989). Induction of pancreatic inﬂammation
after ethionine treatment in rats promoted
the transformation of benign pancreatic aci-
nar tumors into malignant tumors, and this
transformation was associated with the
appearance of mutated p53 protein (Bednarz
and Olewinski 2002).
The generation of the DLC-related pathol-
ogy in the pancreas may be related to a variety
of factors [e.g., the induction of drug-metabo-
lizing enzymes such as cytochrome P450 isoen-
zymes, down-regulation of cholecystokinin
(CCK), perturbations in the vitamin A homeo-
stasis, or other mechanisms] that act either
independently or concomitantly to promote
the development of pancreatic damage.
An increase in CYP1A1 and CYP1A2 is a
hallmark response to DLCs and is directly
linked to binding and activation of the AhR by
DLCs (Whitlock 1993). This is mediated by
binding of the AhR complex to dioxin
response elements present in the 5´ flanking
region of the gene. In one study, the AhR was
expressed in all tissues examined (Dolwick
et al. 1993) with a deﬁnite tissue speciﬁcity in
level of expression and diversity of response,
indicating that DLCs may be likely to exert
some effect in every tissue. In the same study,
Northern blot analysis indicated that human
AhR mRNA is highly expressed in the pan-
creas. One must remember, however, that even
with the same receptor and the same ligand,
both qualitative and quantitative differences
exist in the response to TCDD, depending on
the tissue and species involved.
A relationship among exposure to environ-
mental lipophilic chemicals, elevated levels of
drug-metabolizing enzymes in the pancreatic
exocrine and endocrine cells, and increased
incidences of pancreatic cancer and chronic
pancreatitis may exist in humans (Foster et al.
1993; Standop et al. 2002). Future studies of
samples from our DLC studies in the rat are
aimed at investigating the potential involve-
ment of cytochrome P450 induction in the
pathogenesis of the pancreatic acinar pathology.
The observed acinar atrophy of the pan-
creas may be related in part to the down-regu-
lation of CCK, an important regulator of
pancreatic growth and function (Baldwin
1995; Varga et al. 1998). As shown by Lee
et al. (2000) in samples from the present
PCB-126 study, levels of intestinal CCK are
reduced by PCB-126 exposure. Down-regula-
tion of CCK is likely due to a general
endocrine effect resulting from the reduction
in body weight gain observed with exposure
to DLCs. Previous studies have shown that
increased apoptosis and pancreatic acinar
atrophy occur in Otsuka Long-Evans
Tokushima Fatty rats that lack the CCK-A
receptor gene (Jimi et al. 1997). In addition,
antagonism of CCK action by chemical
(devazepide) blockage of the CCK-A receptor
can lead to reduced pancreatic proliferation
(Ohlsson et al. 1995).
TCDD inﬂuences and disturbs vitamin A
dynamics and metabolism; vitamin A metabo-
lites are known to affect the endocrine and
exocrine glandular cell integrity (Fattore et al.
2000; Nilsson and Hakansson 2002; Schmidt
et al. 2003). Certain synthetic retinoids,
administered in the diet for 1 year at a dose of
0.5–2 mmol/kg, have chemopreventive
potential, reducing the progression of pancre-
atic carcinomas induced in rats by ﬁve weekly
injections of azaserine (Longnecker et al.
1983). More studies are required to deter-
mine the presence or absence of disturbed vit-
amin A metabolism in Sprague-Dawley rats
exposed to DLCs; the biologic relevance of
disturbed vitamin A metabolism to the patho-
genesis of exocrine-gland pathology remains
to be elucidated.
Chronic inflammation is associated with
oxidative stress, which leads to DNA damage
and cancer promotion in experimental studies
and clinical cases. In a study of inhalation
exposure to indium phosphide, a pulmonary
carcinogen, severe pulmonary inflammation
occurred that correlated with the infiltration
of reactive oxygen-generating immune cells,
and macrophages exhibited high levels of the
inducible forms of nitric oxide synthase
(i-NOS) and cyclo-oxygenase (COX-2)
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(Gottschling et al. 2001). Nitric oxide pro-
motes tumor progression (Orucevic et al.
1999), and similarly, COX-2–derived
prostanoids contribute to the progression of
hyperplasia in nearby epithelial cells (Fosslien
2000). In humans, chronic pancreatitis has
been implicated in 3–4% of pancreatic cancers
(Maisonneuve and Lowenfels 1999, 2002). In
our investigation, however, the severity of the
range of nonneoplastic changes (e.g., degener-
ation and inﬂammation) in the exocrine pan-
creas of treated animals with acinar cell tumors
did not indicate a higher grade of severity
compared with other animals in the same
groups without such tumors. Our data, there-
fore, do not to support the notion that
chronic inflammation in the pancreas may
promote carcinogenesis in this organ.
Our studies were not designed to measure
the levels of islet-related hormones in the
blood, and the relative number of islets/area of
pancreatic tissue was not evaluated. Other
studies in rats, however, have shown that
TCDD treatment (25 and 125 ng/kg) reduces
the serum levels of insulin and glucagon.
Because the damage in the pancreas of animals
exposed to DLCs was widespread, including
alterations to cell membranes and arteritis, we
speculate that the functionality and integrity of
the islets were probably also affected (Ebner
et al. 1993; Gorski et al. 1988). No treatment-
related histopathologic change was observed in
the islets of Langerhans in rats treated with
these DLCs; however, the hormonal function
of the islets was not monitored in these studies.
Because of the widespread involvement of the
exocrine pancreas, as well as the observed dam-
age to the blood vessels, we can speculate that
alterations in islets of Langerhans–derived hor-
monal levels in the serum may have occurred.
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